Alkermes plc (ALKS)
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALKS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.55B
- Forward P/E
- 33.21
- EPS (TTM)
- -$0.01
- Dividend yield
- None
- 52-week range
- 27.00 – 55.67
- Day range
- 44.83 – 46.89
- Volume / Avg
- 1.08M / 1.90M
- Beta
- —
- Shares outstanding
- 168.04M
52-week range
ALKS stock today
On Nov 20, ALKS ended the session at $44.94, shedding $1.24 (2.69%), versus the S&P 500's 3.70% decline. Shares are 19.3% below their 52-week high of $55.67, set on Jul 7, 2026 and 66.4% above the 52-week low of $27.00, in the middle of the past year's range. ALKS is up 60.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 57.1%.
Alkermes has posted a net loss over the last twelve months (EPS of -$0.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alkermes
Company profileAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Blair C. Jackson
- Headquarters
- Dublin
- Employees
- 2,050
- IPO year
- 1991
- Website
- alkermes.com
Financial highlights
Full financialsIn fiscal 2025, Alkermes generated $1.48 billion in revenue, down 5.2% from fiscal 2024, its first annual decline since 2024. Net income was $241.7 million (-34.2% year over year), for a net margin of 16.4% versus a median of -4.1% in the prior 5 years. Gross margin was 86.7% (up from 84.2%) and operating margin 17.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Growth | -5.25% | -6.36% | +49.61% | -5.28% | +13.00% |
| Net income | $241.66M | $367.07M | $355.76M | $-158.27M | $-48.17M |
| EPS (diluted) | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$57.74+28.48%
- Strong buy 3
- Buy 12
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.49 vs $-0.08
- Surprise
- +712.50%
ALKS news
All ALKS news- Alkermes plc Enters Settlement Agreement With Teva Over LYBALVI Patent LitigationNasdaq
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesNasdaqALKS, ROIV
- Alkermes plc Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesNasdaqALNY, ALKS
- Alkermes to Report Third Quarter Financial Results on November 3, 2026Business Wire
- HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?NasdaqHRMY, ALKS, JAZZ
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayNasdaqALKS, NBIX, ACAD, AXSM
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290NasdaqALKS, RGEN, PGEN
Alkermes peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs ALKS |
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs ALKS |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs ALKS |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs ALKS |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs ALKS |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs ALKS |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs ALKS |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs ALKS |
Indexes, lists and sector
Alkermes stock FAQ
What is Alkermes's stock price today?
ALKS last traded at $44.94 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.
Does Alkermes pay a dividend?
No. Alkermes does not currently pay a regular cash dividend.
Who is Alkermes's CEO?
Mr. Blair C. Jackson is the chief executive officer of Alkermes plc, which has about 2,050 employees.
Has ALKS ever split its stock?
Yes. The most recent ALKS stock split was a 2-for-1 split on May 15, 2000.
What is the ALKS 52-week high?
The 52-week high for ALKS is $55.67 and the 52-week low is $27.00. The stock is currently 19.3% below its high.